Showing 51-60 of 9094 results for "".
Learn More About REVIAN® Red Hair Growth System
https://practicaldermatology.com/topics/hair-nails/learn-more-about-revian-red-hair-growth-system/19750/Discover a new option for hair loss patients! REVIAN Red is a patented dual-band LED wireless cap for at-home use ten minutes daily. Click Here to Become a REVIAN Red Professional. REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton clAesthetics Update: A Q&A With Modern Aesthetics® editors Saami Khalifian, MD, and Kay Durairaj, MD, FACS
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aesthetics-update-a-qa-with-modern-aesthetics-editors-saami-khalifian-md-and-kay-durairaj-md-facs/29203/The world of aesthetic medicine is rapidly evolving, from next-generation polynucleotides and biostimulators to shifts in patient demands and perceptions of beauty. To discuss the latest trends in aesthetics, Practical Dermatology® turned to its sister publication, Modern Aesthetics®, and new ChiefHarnessing AI for Dermatology Residents
https://practicaldermatology.com/issues/may-june-2025/harnessing-ai-for-dermatology-residents/35915/Dermatology residents face the dual challenge of delivering high-quality patient care while continually advancing their medical knowledge and research skills.Cosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.Biosimilar Recommended; Saunders to Head New Pfizer/Allergan Organization
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-biosimilar-recommended-saunders-to-head-new-pfizer-allergan-organization/18825/An FDA committee has recommended Pfizer's Inflectra, biosimilar to infliximab, developed by Celltrion. Sunbelt Melanoma Trial finds no benefit for IFN in Phase III melanoma. Pfizer/Allergan provides details on structure of new organization and announces leadership, including President and COO BrentEradicating the Itch of Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/eradicating-the-itch-of-atopic-dermatitis/23947/Emerging treatments explore alternative pathways to stop itching at the source.Treating Severe Acne in Transgender Patients: An Update
https://practicaldermatology.com/columns/clinical-focus-1/treating-severe-acne-in-transgender-patients-an-update/23472/Understanding the implications of isotretinoin use in FTM acne patients.Acne and Rosacea: Quality of Life and Lifestyle Insights
https://practicaldermatology.com/topics/acne-rosacea/acne-and-rosacea-quality-of-life-and-lifestyle-insights/23516/Acne and rosacea have causes and effects well beyond the skin.Approvals in Psoriasis and Skin Cancer Highlight a Year of Innovation in Skin Disease Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/approvals-in-psoriasis-and-skin-cancer-highlight-a-year-of-innovation-in-skin-disease-management/21069/After periods of low drug approval rates, the last year brought several new agents to market.Topical Management of Acne-related Post-inflammatory Hyperpigmentation
https://practicaldermatology.com/topics/general-topics/topical-management-of-acne-related-post-inflammatory-hyperpigmentation/21571/Patient education and continued treatment of underlying acne is essential to ensure optimal outcomes with PIH.